New Threat for GlaxoSmithKline: Avandia Spammers

by Jon C. Ogg
24/7 Wall St.



GlaxoSmithKline (GSK) has been under significant pressure of late because of the New England Journal of Medicine showing greatly increased risks of a heart attack for diabetes patients that have taken AVANDIA. The news slowed AVANDIA sales down to a crawl after the published reports showed greatly increased risks of heart attack and death. This wasn't exactly a small drug either, because this was one of the more popular pharmaceuticals used to treat Type II diabetes.

If things were bad enough for GlaxoSmithKline, they just got worse. I went out for about an hour or so on an appointment and upon my return there were two separate emails regarding "AVANDIA LAWSUIT INFO" and after opening one to see if there was already a series of class action suits getting traction. I was a bit suspicious since I have never had anything to do with AVANDIA nor with anything related to it.


Continue article at 247WallSt.com




RELATED READING:
- Avandia, ApoE & Heart Disease
- Compare and Contrast: EMEA and FDA on Avandia
- Networks Dramatize Diabetes Drug Dangers



BioHealth Investor.com
______________________